Citations (68)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Jing Yang, Chengsen Shu, Xianfu Shang, Hao Xu & Ning Wei. (2023) Prognostic Value of Systemic Immune-Inflammation Index-Based Nomogram in Patients with Extrahepatic Cholangiocarcinoma Treated by Percutaneous Transhepatic Biliary Stenting Combined with 125I Seed Intracavitary Irradiation. International Journal of General Medicine 16, pages 2081-2094.
Read now
Read now
Yi Chen, Xiaoling Liu, Liyun Huang, Lihong Chen & Bin Wang. (2023) Clinicopathological, etiological and molecular characteristics of intrahepatic cholangiocarcinoma subtypes classified by mucin production and immunohistochemical features. Expert Review of Molecular Diagnostics 23:5, pages 445-456.
Read now
Read now
Lihong Guo, Jie Zhang, Xueqin Liu, Haocong Liu, Yamin Zhang & Jinpeng Liu. (2022) Successful Treatment of Metastatic Gallbladder Carcinoma with PD-L1 Expression by the Combination of PD-1 Inhibitor Plus Bevacizumab with Chemotherapy: A Case Report. OncoTargets and Therapy 15, pages 629-636.
Read now
Read now
Min Deng, Shaohua Li, Qiaoxuan Wang, Rongce Zhao, Jingwen Zou, Wenping Lin, Jie Mei, Wei Wei & Rongping Guo. (2022) Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy. Annals of Medicine 54:1, pages 803-811.
Read now
Read now
Alessandro Rizzo, Angela Dalia Ricci, Laura Lanotte, Lucia Lombardi, Alessandro Di Federico, Giovanni Brandi & Gennaro Gadaleta-Caldarola. (2022) Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects. Expert Opinion on Investigational Drugs 31:6, pages 557-565.
Read now
Read now
Alessandro Rizzo & Angela Dalia Ricci. (2022) Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert Opinion on Investigational Drugs 31:6, pages 549-555.
Read now
Read now
Alessandro Rizzo, Antonio Cusmai, Gennaro Gadaleta-Caldarola & Gennaro Palmiotti. (2022) Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?. Expert Review of Gastroenterology & Hepatology 16:4, pages 333-339.
Read now
Read now
Alessandro Rizzo, Antonio Cusmai, Angela Dalia Ricci, Giovanni Brandi & Gennaro Palmiotti. (2022) Combination systemic therapies with immune checkpoint inhibitors in biliary tract cancer: effective but not enough?. Expert Review of Gastroenterology & Hepatology 16:4, pages 307-310.
Read now
Read now
Alessandro Rizzo & Angela Dalia Ricci. (2022) PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?. Expert Opinion on Investigational Drugs 31:4, pages 415-423.
Read now
Read now
Alessandro Rizzo & Angela Dalia Ricci. (2022) Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon?. Expert Review of Precision Medicine and Drug Development 7:1, pages 50-57.
Read now
Read now
Alessandro Rizzo, Angela Dalia Ricci & Gennaro Gadaleta-Caldarola. (2021) MSI-H/dMMR and cancer immunotherapy: current state and future implications. Expert Review of Precision Medicine and Drug Development 6:6, pages 345-347.
Read now
Read now
Alessandro Rizzo, Angela Dalia Ricci, Gennaro Gadaleta-Caldarola & Giovanni Brandi. (2021) First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Review of Gastroenterology & Hepatology 15:11, pages 1245-1251.
Read now
Read now
Alessandro Rizzo, Angela Dalia Ricci & Giovanni Brandi. (2021) Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?. Expert Review of Precision Medicine and Drug Development 6:3, pages 217-224.
Read now
Read now
Articles from other publishers (55)
Adil Parvez, Furqan Choudhary, Priyal Mudgal, Rahila Khan, Kamal A. Qureshi, Humaira Farooqi & Ashok Aspatwar. (2023) PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Frontiers in Immunology 14.
Crossref
Crossref
Xiaoxue Ren, Mingle Huang, Weixiang Weng, Yubin Xie, Yifan Wu, Shenghua Zhu, Ying Zhang, Dongming Li, Jiaming Lai, Shunli Shen, Jie Lin, Ming Kuang, Xiaoxing Li, Jun Yu & Lixia Xu. (2023) Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application. Cell Reports Medicine 4:11, pages 101277.
Crossref
Crossref
Zhangjun Cheng, Nuo Cheng, Xuewu Tang, Facai Yang, Weihu Ma, Qiushi Yu, Haolan Tang, Qianru Xiao & Zhengqing Lei. (2023) miR-552 promotes the proliferation and metastasis of intrahepatic cholangiocarcinoma by targeting FOXO1. Experimental Cell Research 431:1, pages 113741.
Crossref
Crossref
Wenji Liu, Jie Peng, Yixin Wu, Zuxiang Ye, Zhen Zong, Rui Wu & Hui Li. (2023) Immune and inflammatory mechanisms and therapeutic targets of gout: An update. International Immunopharmacology 121, pages 110466.
Crossref
Crossref
Yunfeng Li, Chaochao Tan, Xinmin Yin, Siwei Zhu, Rongyao Cai, Chunhong Liao, Yifei Wu, Qihong Zeng, Chengzhi Cai, Wang Xie, Xiangyu He, Hao‐quan Wen, Guomin Lin, Qingqing He, Tingting He, Peng Gu & Chang‐jun Liu. (2023) Mutational spectrum for guiding the decision of adjuvant treatment in patients with resected biliary tract carcinoma. Cancer Medicine 12:15, pages 16076-16086.
Crossref
Crossref
Charupong Saengboonmee, Supannika Sorin, Sakkarn Sangkhamanon, Surang Chomphoo, Somsiri Indramanee, Wunchana Seubwai, Kanyarat Thithuan, Ching-Feng Chiu, Seiji Okada, Marie-Claude Gingras & Sopit Wongkham. (2023) γ-aminobutyric acid B2 receptor: A potential therapeutic target for cholangiocarcinoma in patients with diabetes mellitus. World Journal of Gastroenterology 29:28, pages 4416-4432.
Crossref
Crossref
Asmita Chopra & Alessandro Paniccia. 2023. Biliary Tract - Review and Recent Progress. Biliary Tract - Review and Recent Progress.
Ziqi Ye, Yanfang Zhang, Jie Chen, Xiaoting Wang, Yun Hong & Qingwei Zhao. (2023) First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: A retrospective real-world study. International Immunopharmacology 120, pages 110344.
Crossref
Crossref
Kainan Lin, Jiasheng Cao, Haibo Chen, Win Topatana, Jingwei Cai, Bin Zhang, Jiahao Hu & Renan Jin. (2023) Research trends in cholangiocarcinoma treatments during the last 3 decades. Heliyon 9:7, pages e17100.
Crossref
Crossref
Yidan Qiao, Jie Chen, Xuemei Wang, Shumei Yan, Jizhou Tan, Baijin Xia, Yongjian Chen, Keming Lin, Fan Zou, Bingfeng Liu, Xin He, Yiwen Zhang, Xu Zhang, Hui Zhang, Xiangyuan Wu & Lijuan Lu. (2023) Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins. Cancer Communications 43:7, pages 788-807.
Crossref
Crossref
Tadahisa Inoue & Masashi Yoneda. (2023) Endoscopic intraductal radiofrequency ablation for extrahepatic cholangiocarcinoma: An update (2023). World Journal of Gastrointestinal Endoscopy 15:6, pages 440-446.
Crossref
Crossref
Longrong Wang, Ning Zhang, Yixiu Wang, Ti Zhang, Weiping Zhu, Anrong Mao, Yiming Zhao & Lu Wang. (2023)
Safety and efficacy of
GEMOX
plus donafenib and tislelizumab as first‐line therapy for advanced epithelial malignant biliary tract cancer
. Cancer Medicine 12:11, pages 12263-12271.
Crossref
Crossref
Michael Ghio & Adarsh Vijay. (2023) Intrahepatic cholangiocarcinoma: Evolving role of neoadjuvant and targeted therapy. Annals of Hepato-Biliary-Pancreatic Surgery 27:2, pages 123-130.
Crossref
Crossref
Angela Dalia Ricci, Rosalba D'Alessandro, Alessandro Rizzo, Annalisa Schirizzi, Simona Vallarelli, Carmela Ostuni, Laura Troiani, Ivan Roberto Lolli, Claudio Lotesoriere & Gianluigi Giannelli. (2023) Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door?. Immunotherapy 15:7, pages 477-486.
Crossref
Crossref
Matthew I Ebia, Kamya Sankar, Arsen Osipov, Andrew E Hendifar & Jun Gong. (2023) TOPAZ-1: a new standard of care for advanced biliary tract cancers?. Immunotherapy 15:7, pages 473-476.
Crossref
Crossref
Pedro Luiz Serrano Uson Junior & Tanios Bekaii-Saab. (2023) Moving beyond single-agent checkpoint inhibition in biliary tract cancers: what is the next frontier?. Immunotherapy 15:7, pages 531-540.
Crossref
Crossref
Reem D Mahmood, Kathryn Graham, Jack Gleeson, Richard A Hubner, Juan W Valle & Mairéad G McNamara. (2023) Targeting PD-1/PD-L1 in biliary tract cancer: role and available data. Immunotherapy 15:7, pages 517-530.
Crossref
Crossref
Guofeng Zhang, Ge Zheng, Haipeng Zhang & Ling Qiu. (2023) MUC1 induces the accumulation of Foxp3+ Treg cells in the tumor microenvironment to promote the growth and metastasis of cholangiocarcinoma through the EGFR/PI3K/Akt signaling pathway. International Immunopharmacology 118, pages 110091.
Crossref
Crossref
Liu Qiang, Li Hong, Xu Jian & Zhou Zhanlin. (2023) HUVECs affect HuT-78 cell apoptosis and cytokine production via the HIF-1α-PD-L1/PD-1 pathway under hypoxia. International Immunopharmacology 118, pages 110010.
Crossref
Crossref
Ava Safaroghli-Azar, Fatemeh Emadi, Jimma Lenjisa, Laychiluh Mekonnen & Shudong Wang. (2023) Kinase inhibitors: Opportunities for small molecule anticancer immunotherapies. Drug Discovery Today 28:5, pages 103525.
Crossref
Crossref
Xiang Dong, Zewu Zhang, Qin Zhang, Lu Chen, Guangtai Cao, Chen Liu, Tianqiang Song, Wei Lu & Wei Zhang. (2022) Triple therapy in biliary tract cancers: GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy. Journal of Cancer Research and Clinical Oncology 149:5, pages 1917-1927.
Crossref
Crossref
Tehmina Habib, Mohammad Abu-Abaa & Neel Gandhi. (2023) A Case of Advanced Multifocal Cholangiocarcinoma With Excellent Response to Pembrolizumab. Cureus.
Crossref
Crossref
Yaoqun Wang, Ningyuan Wen, Shaofeng Wang, Guilin Nie, Yuan Tian, Jiong Lu & Bei Li. (2023) Chemotherapy and targeted therapy for advanced biliary tract cancers: an umbrella review. BMC Cancer 23:1.
Crossref
Crossref
Annalisa Schirizzi, Giampiero De Leonardis, Vincenza Lorusso, Rossella Donghia, Alessandro Rizzo, Simona Vallarelli, Carmela Ostuni, Laura Troiani, Ivan Roberto Lolli, Gianluigi Giannelli, Angela Dalia Ricci, Rosalba D’Alessandro & Claudio Lotesoriere. (2023) Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues. Cancers 15:8, pages 2376.
Crossref
Crossref
Shuiling Jin, Ruihua Zhao, Chuang Zhou, Qian Zhong, Jianxiang Shi, Chang Su, Qinglong Li, Xiaoxing Su, Huabin Chi, Xu Lu, Guozhong Jiang, Renyin Chen, Jinming Han, Miao Jiang, Shishi Qiao, Jingjing Liu, Min Song, Lijie Song, Yabing Du, Zhiwei Chang, Meng Wang, Meilian Dong, Yali Zhong, Pu Yu, Xiaojian Zhang & Hong Zong. (2022)
Feasibility and tolerability of sintilimab plus anlotinib as the second‐line therapy for patients with advanced biliary tract cancers: An open‐label, single‐arm, phase
II
clinical trial
. International Journal of Cancer 152:8, pages 1648-1658.
Crossref
Crossref
Zefeng Shen, Liye Tao, Jingwei Cai, Junhao Zheng, Yubin Sheng, Zaibo Yang, Linghan Gong, Chao Song, Jiaqi Gao, Hanning Ying, Junjie Xu & Xiao Liang. (2023) Safety and feasibility of laparoscopic liver resection for intrahepatic cholangiocarcinoma: a propensity score-matched study. World Journal of Surgical Oncology 21:1.
Crossref
Crossref
Tianyin Ma, Zhang Chen, Yibo Chai, Xiangdong Gongye, Peng Xia, Chenming Qu, Ming Tian & Yufeng Yuan. (2023) Research progress on immunotherapy targeting the tumor immune microenvironment for cholangiocarcinoma*. Oncology and Translational Medicine 9:2, pages 49-55.
Crossref
Crossref
Paksiree Saranaruk, Sakda Waraasawapati, Yaovalux Chamgramol, Kanlayanee Sawanyawisuth, Natnicha Paungpan, Narumon Somphud, Chaisiri Wongkham, Seiji Okada, Sopit Wongkham & Kulthida Vaeteewoottacharn. (2023)
Dense GM-CSFR
α
-expressing immune infiltration is allied with longer survival of intrahepatic cholangiocarcinoma patients
. PeerJ 11, pages e14883.
Crossref
Crossref
Fei Song, Chang-Liang Lu, Cheng-Gui Wang, Chen-Wei Hu, Yu Zhang, Tian-Lun Wang, Lu Han & Zhong Chen. (2023) Uncovering the mechanism of Kang-ai injection for treating intrahepatic cholangiocarcinoma based on network pharmacology, molecular docking, and in vitro validation. Frontiers in Pharmacology 14.
Crossref
Crossref
Ling Li, Yang Zhou, Yicheng Zhang, Haijie Hu, Hai-Quan Mao & Florin M. Selaru. (2023) A combination therapy of bortezomib, CXCR4 inhibitor, and checkpoint inhibitor is effective in cholangiocarcinoma in vivo. iScience 26:3, pages 106095.
Crossref
Crossref
Yong Jiang, Liyong Jiang, Hongxin Li, Shuai Yuan, Songhan Huang, Yingda Fu, Shenhao Li, Feiyu Li, Qingbin Li, Xiangyu Yan, Ji Chen & Jun liu. (2023) Adjuvant chemoradiotherapy in resected gallbladder cancer: A SEER-based study. Heliyon 9:3, pages e14574.
Crossref
Crossref
Chae Hwa Kwon, Hyung Il Seo, Dong Uk Kim, Sung Yong Han, Suk Kim, So Jeong Lee & Da Ye Jeon. (2023) HER2 status based on breast cancer guidelines as a useful prognostic marker of T2 gallbladder cancer. European Journal of Surgical Oncology 49:2, pages 392-398.
Crossref
Crossref
Wei Zhang, Chu Luo, Zun-Yi Zhang, Bi-Xiang Zhang & Xiao-Ping Chen. (2023) Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review. Frontiers in Immunology 13.
Crossref
Crossref
Jing Wang, Chan Zhang & Dong Yan. (2023) The Impact of a History of Different Other Cancers on the Long-Term Outcomes of Patients with Gallbladder Cancer: A Propensity Score–Adjusted, Population-Based Study. Technology in Cancer Research & Treatment 22.
Crossref
Crossref
Qin Liu, Yuanyuan Chen, Yan Hu & Jiyuan Yang. (2023) Clinical research progress of targeted therapy combined with immunotherapy for advanced cholangiocarcinoma. Cancer Treatment and Research Communications 37, pages 100771.
Crossref
Crossref
Charbel Elias, Youssef H. Zeidan, Youssef Bouferraa, Deborah Mukherji, Sally Temraz, Maya Charafeddine, Monita Al Darazi & Ali Shamseddine. (2022) A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO). BMC Cancer 22:1.
Crossref
Crossref
Morgan Marriott, Brittany Post & Lipika Chablani. (2022) A Comparison of Cancer Vaccine Adjuvants in Clinical Trials. Cancer Treatment and Research Communications, pages 100667.
Crossref
Crossref
Tingjie Wang, Chuanrui Xu, Dan Xu, Xiaofei Yang, Yaxin Liu, Xiujuan Li, Zihang Li, Ningxin Dang, Yi Lv, Zhijing Zhang, Lei Li & Kai Ye. (2022) Integrating cell interaction with transcription factors to obtain a robust gene panel for prognostic prediction and therapies in cholangiocarcinoma. Frontiers in Genetics 13.
Crossref
Crossref
Meng-Ye He, Fei-Fei Yan, Kai-Li Cen & Peng Shen. (2022) Long survival after immunotherapy plus paclitaxel in advanced intrahepatic cholangiocarcinoma: A case report and review of literature. World Journal of Clinical Cases 10:32, pages 11889-11897.
Crossref
Crossref
Alessandro Rizzo, Angela Dalia Ricci & Giovanni Brandi. (2022) Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update. Journal of Personalized Medicine 12:11, pages 1788.
Crossref
Crossref
Alessandro Rizzo, Massimiliano Salati, Giorgio Frega, Valeria Merz, Francesco Caputo, Alessandro Di Federico, Andrea Palloni, Riccardo Carloni, Angela Dalia Ricci, Gennaro Gadaleta-Caldarola, Carlo Messina, Andrea Spallanzani, Fabio Gelsomino, Stefania Benatti, Gabriele Luppi, Davide Melisi, Massimo Dominici & Giovanni Brandi. (2022) Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study. Medicina 58:11, pages 1543.
Crossref
Crossref
Alessandro Rizzo, Veronica Mollica, Matteo Santoni & Francesco Massari. (2022) Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer. Journal of Clinical Medicine 11:21, pages 6356.
Crossref
Crossref
Gennaro Gadaleta-Caldarola, Alessandro Rizzo, Vincenzo Dadduzio, Lucia Lombardi, Arianna Gadaleta-Caldarola, Stefania Infusino, Antonio Cusmai, Claudia Citrigno & Gennaro Palmiotti. (2022) Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress. Current Oncology 29:10, pages 7925-7931.
Crossref
Crossref
Buwen Zhang & Weiyun Yao. (2022) Prognostic role of the systemic immune-inflammation index in biliary tract cancers: a meta-analysis of 3,515 patients. World Journal of Surgical Oncology 20:1.
Crossref
Crossref
Feiyu Li, Yong Jiang, Liyong Jiang, Qingbin Li, Xiangyu Yan, Songhan Huang, Ji Chen, Shuai Yuan, Yingda Fu & Jun Liu. (2022) Effect of lymph node resection on prognosis of resectable intrahepatic cholangiocarcinoma: A systematic review and meta-analysis. Frontiers in Oncology 12.
Crossref
Crossref
Giovanni Brandi & Alessandro Rizzo. (2022) IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience?. International Journal of Molecular Sciences 23:18, pages 10869.
Crossref
Crossref
Hong-Li Wang, Zhi-Gang Wang & Shu-Lin Liu. (2022) Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy. Molecules 27:17, pages 5607.
Crossref
Crossref
Pedro Luiz Serrano Uson Junior & Raphael LC Araujo. (2022) Immunotherapy in biliary tract cancers: Current evidence and future perspectives. World Journal of Gastrointestinal Oncology 14:8, pages 1446-1455.
Crossref
Crossref
Alessandro Rizzo, Riccardo Carloni, Angela Dalia Ricci, Alessandro Di Federico, Deniz Can Guven, Suayib Yalcin & Giovanni Brandi. (2022) Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis. Journal of Personalized Medicine 12:8, pages 1247.
Crossref
Crossref
Evangelos Koustas, Eleni-Myrto Trifylli, Panagiotis Sarantis, Nikolaos Papadopoulos, Eleni Karapedi, Georgios Aloizos, Christos Damaskos, Nikolaos Garmpis, Anna Garmpi, Kostas A. Papavassiliou, Michalis V. Karamouzis & Athanasios G. Papavassiliou. (2022) Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer—Current Treatment Options and Future Perspectives. International Journal of Molecular Sciences 23:12, pages 6664.
Crossref
Crossref
Savannah S. Liddell, Sakti Chakrabarti, Grant A. Wintheiser, Tyler J. Zemla, Qian Shi, Sri Harsha Tella, Zhaohui Jin, Vanessa B. Wookey, Hind Hassan, Nguyen H. Tran, Mitesh J. Borad & Amit Mahipal. (2022) Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer. JCO Precision Oncology:6.
Crossref
Crossref
Roberta Giorgione, Matteo Risaliti, Ilenia Bartolini, Gemma Rossi, Serena Pillozzi, Paolo Muiesan, Antonio Taddei & Lorenzo Antonuzzo. (2022) The emerging role of immunotherapy in biliary tract cancer: a review of new evidence and predictive biomarkers. Immunotherapy 14:7, pages 567-576.
Crossref
Crossref
Xiuxiang Tan, Jan Bednarsch, Mika Rosin, Simone Appinger, Dong Liu, Georg Wiltberger, Juan Garcia Vallejo, Sven Arke Lang, Zoltan Czigany, Shiva Boroojerdi, Nadine T. Gaisa, Peter Boor, Roman David Bülow, Judith De Vos-Geelen, Liselot Valkenburg-van Iersel, Marian C. Clahsen-van Groningen, Evelien J. M. de Jong, Bas Groot Koerkamp, Michail Doukas, Flavio G. Rocha, Tom Luedde, Uwe Klinge, Shivan Sivakumar, Ulf Peter Neumann & Lara Rosaline Heij. (2022) PD-1+ T-Cells Correlate with Nerve Fiber Density as a Prognostic Biomarker in Patients with Resected Perihilar Cholangiocarcinoma. Cancers 14:9, pages 2190.
Crossref
Crossref
Nikolaos Charalampakis, Georgios Papageorgiou, Sergios Tsakatikas, Rodanthi Fioretzaki, Christo Kole, Stylianos Kykalos, Maria Tolia & Dimitrios Schizas. (2021) Immunotherapy for cholangiocarcinoma: a 2021 update. Immunotherapy 13:13, pages 1113-1134.
Crossref
Crossref
Alessandro Rizzo. (2021) Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors. Medicina 57:5, pages 458.
Crossref
Crossref